Teleflex Incorporated (NYSE:TFX) insider have most recently took part in a trading activity. On Jun 21, 2017 Haggerty Gretchen R, Director bought 1,000 shares having total worth of $203,820 at the price of $203.82 per share, following the transaction a total of 1,760 shares owned by Haggerty Gretchen R.
The stock has experienced a total of 4 insider trades in the past three months. These trades include 4 sell activities .Furthermore, over the past 12 months , the stock was traded 5 times by insiders. In 5 of these trades, the insider was a seller .
|Time Frame||Number of Insider Buy||Number of Insider Sell||Stock Price Change(%)|
Shares of Teleflex Incorporated (NYSE:TFX) traded down 0.03% on Jun 21, 2017, hitting $203.45. 168,006 shares of the company’s stock traded hands. Teleflex Incorporated has a 52 week low of $126 and a 52 week high of $210.37. The company’s market cap is $7,410 million.
Teleflex Incorporated (NYSE:TFX) last announced its earnings results on May 4, 2017. The company reported 1.80 earnings per share (EPS) for the quarter, higher than the consensus estimate of 1.69 by $0.11. The company had revenue of $488 million for the quarter, compared to the consensus estimate of $472 million. During the same quarter in the previous year, the company posted 1.52 earnings per share. The company’s revenue for the quarter was up 15% on a year-over-year basis.
|earnings per share||1.80||2.13||1.80||1.89||1.52||2.01||1.60||1.42||1.30||1.43|
Teleflex Inc. is a Delaware Corporation incorporated in 1943. The Company is a global provider of medical technology products that enhance clinical benefits, improve patient and provider safety and reduce total procedural costs. To achieve this mission, Teleflex is committed to the following: investing in technology and developing its pipeline; leveraging and building its core franchises and distribution channels; attracting, developing and retaining talented employees around the world; and continuing to build financial strength by expanding its margins and maintaining strong cash flow all in an effort to successfully grow its reputation as a solid investment and a profitable, strong employer. It primarily designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for common diagnostic and therapeutic procedures in critical care and surgical applications. It sells its products to hospitals and healthcare providers in more than 130 countries through a combination of its direct sales force and distributors. The Company’s products are used in a wide variety of markets and are not dependent upon any one end-market or procedure. Teleflex is entirely focused on healthcare and operates as a diversified, global medical technology company. It provides a broad-based platform of products, which it categorizes into four groups: Critical Care, Surgical Care, Cardiac Care and OEM and Development Services. It is a provider of specialty products for critical care, which is predominantly comprised of single-use products. The large majority of sales for single-use products are made to the hospital/healthcare provider market, with a smaller percentage sold to alternate sites. The Company’s surgical products include: ligation and closure products, including appliers, clips and sutures used in a variety of surgical procedures; access ports used in minimally invasive surgical procedures, including robotic surgery; and fluid management products used for chest drainage. The Company’s surgical products also include hand-held instruments for general and specialty surgical procedures. It markets surgical products under the Deknatel, Pleur-evac, Pilling, Taut and Weck brand names. Products in Cardiac Care category include diagnostic catheters and capital equipment. The Company’s diagnostic catheters include thermodilution and wedge pressure catheters; specialized angiographic catheters, such as Berman and Reverse Berman catheters; therapeutic delivery catheters, such as temporary pacing catheters; sheaths for femoral and trans-radial aortic access used in diagnostic and therapeutic procedures; and intra-aortic balloon, or IAB, catheters. Capital equipment includes its intra-aortic balloon pump, or IABP, consoles. IABP products are used to augment oxygen delivery to the cardiac muscle and reduce the oxygen demand after cardiac surgery, serious heart attack or interventional procedures. The IAB and IABP
Latest posts by William White (see all)
- Insider Trading Review: FS Investment Corporation $FSIC - January 13, 2018
- Insider Trader Watch: ENERTOPIA CORP $ENRT - January 13, 2018
- Insider Trading in Focus: Swiss Helvetia Fund, Inc. (The) $SWZ - January 13, 2018